- Gannet BioChem has acquired Laysan Bio, a life sciences company based in Arab, Alabama, to expand its activated polymer and bioconjugation capabilities.
- The acquisition enhances Gannet BioChem’s ability to support partners from early development through GMP manufacturing.
Gannet BioChem has announced the acquisition of Laysan Bio, a life sciences company based in Arab, Alabama. The transaction is intended to strengthen Gannet BioChem’s capabilities across activated polymer technologies, including PEG reagents and bioconjugation, and to enhance support for partners from early development through GMP manufacturing.
Founded nearly two decades ago, Laysan Bio supplies catalogued, custom, and compliant activated polymer reagents to academic, biotechnology, and pharmaceutical organisations. Its technical expertise, quality systems, and programme support capabilities are expected to complement Gannet BioChem’s existing platform and extend its reach across advanced therapeutics, drug delivery, and medical device programmes.
“This acquisition meaningfully expands our technical depth and manufacturing flexibility across activated polymers and bioconjugation.”
Nicholas Shackley, Chief Executive Officer of Gannet BioChem
He added that Laysan Bio’s experience and customer relationships align with Gannet BioChem’s mission to build a comprehensive platform supporting partners from discovery through commercial manufacturing.
Jon McKannan, President of Laysan Bio, said the transaction represents “an exciting next chapter” for the company and its customers, creating opportunities to scale capabilities, broaden offerings, and accelerate ongoing programmes.
The acquisition aligns with Gannet BioChem’s broader strategy to invest in specialised technologies and talent, with a continued focus on quality, compliance, and long-term customer partnership within its CDMO and contract manufacturing operations.
